Tags

Type your tag names separated by a space and hit enter

[Comparison of outpatient and inpatient costs of moderate and severe exacerbations of chronic obstructive pulmonary disease in Poland].
Pneumonol Alergol Pol. 2008; 76(6):426-31.PA

Abstract

INTRODUCTION

The aim of the study was to examine the direct and indirect costs of COPD exacerbations under usual clinical practice in primary and secondary care from a societal perspective in Poland.

MATERIAL AND METHODS

An observational, prospective study was conducted among patients with exacerbation of moderate or severe COPD. Seventy-three patients were included in the study - 39 treated in hospital (HC) and 34 treated in ambulatory care (AC). The direct costs included the cost of drugs, diagnostic tests, in-hospital and outpatient care. The indirect costs included costs of transportation to the health-care provider and work days lost.

RESULTS

The mean duration of COPD exacerbation did not differ significantly between the groups [HC: 11.2 (CI 95%: 9.6-12.8) days; AC: 10.8 (CI 95%: 9.1-12.1); p > 0.05]. The total health-care cost per exacerbation was EUR 1197 (4137.9 PLN) in secondary care (the HC group), and it was 6 times higher than the total cost of exacerbation in primary care (the AC group) - EUR 199.8 (446.9 PLN). The costs of drugs and diagnostic tests were significantly higher in the HC group than in the AC group; however, it was the cost of in-hospital stay and medical visits in the HC group that most influenced expenditure related to COPD exacerbations, as they were 27 times higher than in the AC group.

CONCLUSIONS

In Poland the costs of COPD exacerbation managed in secondary care are 6-fold higher than in primary care. Therefore, the decisions about admission of patients with COPD exacerbation to hospital should be made carefully.

Authors+Show Affiliations

Zakład Immunologii i Alergologii Klinicznej Wojskowego Instytutu Medycznego w Warszawie Kierownik. krozyk@poczta.onet.plNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
English Abstract
Journal Article

Language

pol

PubMed ID

19173191

Citation

Jahnz-Rózyk, Karina, et al. "[Comparison of Outpatient and Inpatient Costs of Moderate and Severe Exacerbations of Chronic Obstructive Pulmonary Disease in Poland]." Pneumonologia I Alergologia Polska, vol. 76, no. 6, 2008, pp. 426-31.
Jahnz-Rózyk K, Targowski T, From S. [Comparison of outpatient and inpatient costs of moderate and severe exacerbations of chronic obstructive pulmonary disease in Poland]. Pneumonol Alergol Pol. 2008;76(6):426-31.
Jahnz-Rózyk, K., Targowski, T., & From, S. (2008). [Comparison of outpatient and inpatient costs of moderate and severe exacerbations of chronic obstructive pulmonary disease in Poland]. Pneumonologia I Alergologia Polska, 76(6), 426-31.
Jahnz-Rózyk K, Targowski T, From S. [Comparison of Outpatient and Inpatient Costs of Moderate and Severe Exacerbations of Chronic Obstructive Pulmonary Disease in Poland]. Pneumonol Alergol Pol. 2008;76(6):426-31. PubMed PMID: 19173191.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Comparison of outpatient and inpatient costs of moderate and severe exacerbations of chronic obstructive pulmonary disease in Poland]. AU - Jahnz-Rózyk,Karina, AU - Targowski,Tomasz, AU - From,Sławomir, PY - 2009/1/29/entrez PY - 2009/1/29/pubmed PY - 2009/4/17/medline SP - 426 EP - 31 JF - Pneumonologia i alergologia polska JO - Pneumonol Alergol Pol VL - 76 IS - 6 N2 - INTRODUCTION: The aim of the study was to examine the direct and indirect costs of COPD exacerbations under usual clinical practice in primary and secondary care from a societal perspective in Poland. MATERIAL AND METHODS: An observational, prospective study was conducted among patients with exacerbation of moderate or severe COPD. Seventy-three patients were included in the study - 39 treated in hospital (HC) and 34 treated in ambulatory care (AC). The direct costs included the cost of drugs, diagnostic tests, in-hospital and outpatient care. The indirect costs included costs of transportation to the health-care provider and work days lost. RESULTS: The mean duration of COPD exacerbation did not differ significantly between the groups [HC: 11.2 (CI 95%: 9.6-12.8) days; AC: 10.8 (CI 95%: 9.1-12.1); p > 0.05]. The total health-care cost per exacerbation was EUR 1197 (4137.9 PLN) in secondary care (the HC group), and it was 6 times higher than the total cost of exacerbation in primary care (the AC group) - EUR 199.8 (446.9 PLN). The costs of drugs and diagnostic tests were significantly higher in the HC group than in the AC group; however, it was the cost of in-hospital stay and medical visits in the HC group that most influenced expenditure related to COPD exacerbations, as they were 27 times higher than in the AC group. CONCLUSIONS: In Poland the costs of COPD exacerbation managed in secondary care are 6-fold higher than in primary care. Therefore, the decisions about admission of patients with COPD exacerbation to hospital should be made carefully. SN - 0867-7077 UR - https://www.unboundmedicine.com/medline/citation/19173191/[Comparison_of_outpatient_and_inpatient_costs_of_moderate_and_severe_exacerbations_of_chronic_obstructive_pulmonary_disease_in_Poland]_ L2 - http://czasopisma.viamedica.pl/pap/article/view/27861 DB - PRIME DP - Unbound Medicine ER -